[1] Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ 2011;342:d3514. http://dx.doi.org/10.1136/bmj.d3514CrossRef
[2] Mueller C, Molokhia M, Perera G, Veronese N, Stubbs B, Shetty H, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol 2018;106:240 − 5. http://dx.doi.org/10.1016/j.exger.2018.02.011CrossRef
[3] GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022;7(2):e105 − 25. http://dx.doi.org/10.1016/S2468-2667(21)00249-8CrossRef
[4] Börsch-Supan A, Brandt M, Hunkler C, Kneip T, Korbmacher J, Malter F, et al. Data resource profile: the survey of health, ageing and retirement in Europe (SHARE). Int J Epidemiol 2013;42(4):992 − 1001. http://dx.doi.org/10.1093/ije/dyt088CrossRef
[5] Thapaliya K, Harris ML, Byles JE. Polypharmacy trajectories among older women with and without dementia: a longitudinal cohort study. Explor Res Clin Soc Pharm 2021;3:100053. http://dx.doi.org/10.1016/J.RCSOP.2021.100053CrossRef
[6] Kristensen RU, Nørgaard A, Jensen-Dahm C, Gasse C, Wimberley T, Waldemar G. Changes in the prevalence of polypharmacy in people with and without dementia from 2000 to 2014: a nationwide study. J Alzheimers Dis 2019;67(3):949 − 60. http://dx.doi.org/10.3233/JAD-180427CrossRef
[7] Survey of Health, Ageing and Retirement in Europe. Release guide 7.1.1. 2020. http://www.share-project.org/fileadmin/pdf_documentation/SHARE_release_guide_7-1-1.pdf. [2022-7-16].http://www.share-project.org/fileadmin/pdf_documentation/SHARE_release_guide_7-1-1.pdf
[8] Kristensen RU, Nørgaard A, Jensen-Dahm C, Gasse C, Wimberley T, Waldemar G. Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study. J Alzheimers Dis 2018;63(1):383 − 94. http://dx.doi.org/10.3233/JAD-170905CrossRef
[9] Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med 2015;13:74. http://dx.doi.org/10.1186/s12916-015-0322-7CrossRef
[10] Mozhaeva I. Inequalities in utilization of institutional care among older people in Estonia. Health Policy 2022;126(7):704 − 14. http://dx.doi.org/10.1016/J.HEALTHPOL.2022.04.008CrossRef